CO2 Laser + Platelet-Rich Plasma Promising Treatment for Vitiligo

This article originally appeared here.
Share this content:
CO<sub>2</sub> Laser &#43; Platelet-Rich Plasma Promising Treatment for Vitiligo
CO2 Laser + Platelet-Rich Plasma Promising Treatment for Vitiligo

MONDAY, Aug. 28, 2017 (HealthDay News) -- Combination of fractional carbon dioxide (CO2) laser with platelet-rich plasma (PRP) injection is a promising treatment for vitiligo, according to a study published online Aug. 20 in the Journal of Cosmetic Dermatology.

Rania Abdelghani, M.D., from Al-Azhar University in Cairo, and colleagues randomly assigned 80 adult patients with localized non-segmental vitiligo to receive four treatment options: fractional CO2 laser, PRP, combined fractional CO2 laser and PRP, or combined fractional CO2 laser and narrowband ultraviolet B (NB-UVB) -- all for two months.

The researchers found that the laser and PRP group achieved the best results for repigmentation and patient satisfaction, with 60 percent of the patients developing repigmentation of more than 50 percent, and 40 percent developing repigmentation of more than 75 percent. In the laser and NB-UVB group, 5 percent developed repigmentation over 75 percent, and 25 percent developed repigmentation over 50 percent. In the laser group, only 10 percent of patients developed repigmentation of more than 75 percent, as did only 20 percent in the PRP group.

"Combination of fractional CO2 laser with PRP injection is a promising treatment for vitiligo, followed by combination of fractional CO2 laser with NB-UVB phototherapy," the authors write. "Both fractional CO2 laser and PRP injection gave poor results if they [were] received alone."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »